CVS Health (CVS) shares surged 5.14% in pre-market trading on Thursday following the release of its impressive second-quarter results and an upward revision of its full-year guidance. The healthcare giant significantly outperformed Wall Street expectations, demonstrating strong performance across its various business segments.
The company reported adjusted earnings per share of $1.81, handily beating the analyst estimate of $1.46. Revenue for the quarter reached $98.92 billion, surpassing the expected $94.50 billion. CVS Health's medical benefit ratio, a key metric in the health insurance industry, came in at 89.9%, lower than the anticipated 91.16%, indicating better cost management in its Aetna insurance business.
Boosted by these strong results, CVS Health raised its full-year 2025 earnings outlook to $6.30-$6.40 per share, up from the previous guidance of $6.00-$6.20 and above the analyst consensus of $6.12. The company attributed this optimistic forecast to improved performance across its pharmacy services, retail/long-term care, and healthcare benefits segments. Despite recording $833 million in litigation charges for the quarter, CVS Health's overall financial health appears robust, instilling confidence in investors and driving the stock's pre-market rally.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.